Active substance
Cyclizine
- US FDA 1
- UK MHRA 15
- NHS prices 2
- WHO EML 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MAREZINE | 50MG/ML | injectable · injection | GLAXOSMITHKLINE | Discontinued | 24 Sep 1954 |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| CYCLIZINE HYDROCHLORIDE 50 MG TABLETS | PL 20072/0241 | AMDIPHARM UK LIMITED | P |
| CYCLIZINE HYDROCHLORIDE 50 MG TABLETS | PL 25298/0046 | BROWN & BURK UK LIMITED | P |
| CYCLIZINE HYDROCHLORIDE 50MG TABLETS | PL 15764/0135 | STRANDHAVEN LIMITED | P |
| CYCLIZINE HYDROCHLORIDE 50MG TABLETS | PL 20117/0216 | MORNINGSIDE HEALTHCARE LIMITED | P |
| CYCLIZINE LACTATE 50 MG/ ML SOLUTION FOR INJECTION | PL 25298/0314 | BROWN & BURK UK LIMITED | POM |
| CYCLIZINE LACTATE 50 MG/ML INJECTION | PL 20072/0010 | AMDIPHARM UK LIMITED | POM |
| CYCLIZINE LACTATE 50 MG/ML INJECTION | PL 20117/0314 | MORNINGSIDE HEALTHCARE LIMITED | POM |
| CYCLIZINE LACTATE 50 MG/ML SOLUTION FOR INJECTION | PL 01502/0104 | HAMELN PHARMA LTD | POM |
| CYCLIZINE LACTATE 50 MG/ML SOLUTION FOR INJECTION | PL 01883/0270 | MACARTHYS LABORATORIES LIMITED | POM |
| CYCLIZINE LACTATE 50 MG/ML SOLUTION FOR INJECTION | PL 39280/0012 | SYNCHRONY PHARMA LIMITED | POM |
| CYCLIZINE LACTATE 50 MG/ML SOLUTION FOR INJECTION | PL 56854/0020 | ORBIT PHARMA LIMITED | POM |
| CYCLIZINE LACTATE 50MG/ML INJECTION | PL 35104/0021 | PHOENIX LABS UNLIMITED COMPANY | POM |
| CYCLIZINE LACTATE 50MG/ML SOLUTION FOR INJECTION | PL 15764/0209 | STRANDHAVEN LIMITED | POM |
| VALOID 50MG TABLETS | PL 20072/0241 | AMDIPHARM UK LIMITED | P |
| VALOID INJECTION | PL 20072/0010 | AMDIPHARM UK LIMITED | POM |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Cyclizine 50mg tablets | £3.09 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cyclizine 50mg/1ml solution for injection ampoules | £3.24 | 5 ampoule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 2.3. Medicines for other common symptoms in palliative care · core
Palliative care
Parenteral > General injections > unspecified: 50 mg per mL (lactate) (EMLc) | Oral > Solid > tablet: 50 mg (hydrochloride) (EMLc)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.